Jasper Therapeutics (NASDAQ:JSPR) Price Target Cut to $48.00 by Analysts at Royal Bank of Canada

Jasper Therapeutics (NASDAQ:JSPR - Free Report) had its target price cut by Royal Bank of Canada from $68.00 to $48.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other equities research analysts also recently issued reports on the stock. HC Wainwright reissued a "buy" rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, October 24th. BMO Capital Markets assumed coverage on Jasper Therapeutics in a report on Friday, December 6th. They set an "outperform" rating and a $63.00 target price for the company. Finally, JMP Securities reissued a "market outperform" rating and issued a $70.00 price target on shares of Jasper Therapeutics in a research note on Monday. Ten investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $70.88.

Jasper Therapeutics Trading Down 60.5 %

Shares of NASDAQ:JSPR traded down $10.72 during trading on Thursday, hitting $6.99. 6,600,423 shares of the company's stock traded hands, compared to its average volume of 1,690,942. The company has a 50-day moving average price of $21.66 and a 200-day moving average price of $20.37. Jasper Therapeutics has a 52 week low of $6.61 and a 52 week high of $31.01. The company has a market cap of $104.86 million, a price-to-earnings ratio of -1.47 and a beta of 2.18.

Institutional Trading of Jasper Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Samsara BioCapital LLC raised its holdings in shares of Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company's stock valued at $10,997,000 after purchasing an additional 59,642 shares during the period. Wellington Management Group LLP acquired a new position in Jasper Therapeutics during the third quarter worth approximately $447,000. Ally Bridge Group NY LLC raised its stake in Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock valued at $7,514,000 after buying an additional 180,852 shares during the period. Braidwell LP acquired a new stake in shares of Jasper Therapeutics in the third quarter valued at approximately $9,091,000. Finally, FMR LLC bought a new position in shares of Jasper Therapeutics during the 3rd quarter worth approximately $722,000. Institutional investors own 79.85% of the company's stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.